Estrogen vs Estradiol: What Is the Difference and Why Does It Matter for Hormone Therapy?

Key Takeaways

• Estrogen vs estradiol is not an interchangeable comparison; estradiol is a specific type of estrogen and the primary estrogen produced by women before menopause.
• Many people asking about estrogen versus estradiol are actually comparing bioidentical estradiol to synthetic conjugated equine estrogens (CEE).
• Bioidentical estradiol is structurally identical to the hormone naturally produced by the ovaries.
• Research suggests estradiol therapy may provide better symptom relief and a more favorable safety profile than CEE in menopausal women.
• Bioidentical hormone therapy can help address symptoms and health risks associated with menopause.
• Understanding the different types of estrogen is essential when evaluating hormone treatment options.

Estrogen vs Estradiol: Understanding the Difference

When referring to menopausal hormone therapy, some terms are used interchangeably that should not be. One of the most common misconceptions in menopause care is assuming that estrogen and estradiol are the same thing. While estradiol is a form of estrogen, not all estrogen products contain bioidentical estradiol. When discussing estrogen vs estradiol, understanding the source, structure, and biological activity of each hormone is critical. 

The most common FDA-approved “estrogen” that prescribers utilize is synthetic conjugated equine estrogens (CEE).[1] As stated in its name, this product is derived from the urine of pregnant mares which contains components that are not bioidentical to what a woman naturally makes and therefore elicits many unfavorable side effects.[2] In contrast, bioidentical estradiol is chemically identical to the estradiol naturally produced by a woman's ovaries.

Many providers and patients discussing estrogen versus estradiol are actually comparing synthetic CEE with bioidentical estradiol replacement.

Synthetic CEE should never be confused with a woman’s naturally occurring estradiol (E2) that is lost after the final menstrual cycle. This guide will serve as the basis for why estradiol replacement in menopausal women is the safer and more efficacious choice.[2]

• Estrogen vs Estradiol: Understanding the Difference
• When Should Estradiol Be Replaced?
• Why Hormone Replacement Therapy Matters After Menopause
• Types of Estrogen: Comparing CEE and Bioidentical Estradiol
• Safety and Effectiveness of Estradiol Therapy
• Estradiol and Progesterone Therapy: A Common Clinical Approach
• Frequently Asked Questions About Estrogen vs Estradiol
• Conclusion
• Interested in Learning More About Menopause and BHRT?

When Should Estradiol Be Replaced?

Menopause and Hormone Decline

A woman has successfully transitioned into menopause when she has ceased to have a menstrual cycle for twelve consecutive months.[3] Other circumstances that would render a woman into this stage would be a bilateral oophorectomy at the time of a hysterectomy, as the ovaries are responsible for producing hormonal activity. 

The stage leading up to menopause is termed perimenopause. This stage usually begins around age 47 when the menstrual cycle becomes irregular, but can vary with each woman.

Some women experience menopause-associated symptoms such as:

• Mood swings
• Difficulty sleeping
• Difficulty concentrating
• Joint pain
• Breast tenderness
• Headaches
• Vaginal dryness
• Hot flushes

During this time, a woman’s ovaries are still producing estradiol, sometimes to a very high degree; therefore, women in this stage should not be supplemented with exogenous estradiol.[3] 

On the flipside, as women age and are deprived of their estradiol through natural or surgical menopause, they are more at risk for menopause related metabolic changes.[4] The earlier these hormones are replaced (and the closer to the last menstrual cycle), the better the outcome.[4]

Why Hormone Replacement Therapy Matters After Menopause

Many of the symptoms and diseases women report are linked to the loss of their youthful hormones.[3] For many women, hormone replacement therapy, hormone therapy, and estrogen therapy become important considerations as estradiol levels decline with age. 

For instance, as cardiovascular disease is the number one cause of death in women, very few younger women succumb to this disease.[4] As estradiol is lost:

• cardiovascular lipid parameters increase
• bone mineral density decreases
• muscle mass declines
• adipose tissue increases
• skin collagen decreases.[3]  

These are just a few of the changes women face as they age, and many times, they are told this is a normal part of the aging process. 

With all the data now available, providers can better guide their female patients and help them prevent many of the illnesses they are plagued with today.

The Difference Between CEE and Bioidentical Estradiol

To understand estrogen versus estradiol, it is important to understand the different types of estrogen available for menopause treatment.

What Is Conjugated Equine Estrogen (CEE)?

When studying the difference between estradiol and synthetic CEE, one must dive into the pharmacological properties to gain a clearer understanding of why estradiol should be the preferred choice of replacement.

CEE contains a mixture of steroids, all of which exert biological activity in the human female.[2] There are:

• sixteen estrogenic steroids 
• five progestogenic steroids
• three additional androgenic steroids. 

Most are not found naturally in the human body.

The concentrations of these aren’t even clear when studied by liquid chromatography. 

In addition to subjecting the female to animal steroids that are foreign to humans, CEE’s components react and bind differently with estrogen receptor sites, which can lead to adverse symptoms and long-term consequences.  

These side effects can be due to the individual steroids themselves or to the binding affinity and activity, which is largely unpredictable. Unlike bioidentical estradiol (which is identical to what a female normally makes in her youth), CEE only contains about one percent of 17-beta estradiol.

It is this deficit in aging women that should be addressed, and the hormone that should be replaced, and not that of an animal.[2]

Safety Profiles of Estradiol Therapy vs Synthetic Estrogen

Benefits of Estradiol Therapy

Estradiol replacement in menopausal women has a larger safety profile and is effective at symptom management.[5] 

Women reporting night sweats, vaginal dryness, brain fog, hot flushes, and insomnia who were prescribed estradiol reported better symptom relief when compared to CEE.[5-6]

Cardiovascular Outcomes

More importantly, there were fewer incidences of:

• major adverse cardiovascular events (MACE)
• deep vein thrombosis (DVT)
• Alzheimer's disease
• cerebral vascular accidents (CVA)
• breast cancer.[5-14] 

MACE that were studied in this population included acute myocardial infarction (AMI), ischemic/hemorrhagic CVAs, and congestive heart failure (CHF).[7]

 In an American claims data analysis of over 35,000 women, there was a 75% relative risk reduction of MACE in women who were prescribed E2. Perhaps this can be due to inflammation seen with CEE in areas such as coagulation pathways, endothelial function, and vascular tone.[7]

Markers such as an increased C-reactive protein (CRP) that predicts inflammation, have been elevated in patients taking CEE.5,10 In addition to CRP, increased levels of cholesterol and glucose have also been witnessed in CEE patients.[4]

Not only was there an increase in MACE, there was also a 1.5% higher increase in hemorrhagic strokes seen with CEE in a recent retrospective cohort study of almost 100,000 women.[9]

Oral Estradiol, Estrogen Patches, and Other Hormone Therapy Options

While this article focuses on estrogen vs estradiol, providers frequently ask about delivery methods as well.

Common options for estradiol therapy include:

• Oral estradiol
• Transdermal estradiol patches
• Topical estradiol gels and creams
• Vaginal or sublingual estradiol preparations

When comparing oral estradiol vs patch therapy, or evaluating an estrogen patch vs pill, the most important consideration is selecting the hormone formulation that best aligns with the patient's clinical goals and overall treatment plan.

Similarly, discussions about oral estrogen vs patch therapy should distinguish between bioidentical estradiol and synthetic estrogen products, as these hormones have different pharmacologic properties and clinical outcomes.

For further exploration of this topic, consider reading our blog post Oral vs. Transdermal Estradiol: Which Is Better for Menopause Hormone Therapy?

Conclusion

The decision to offer patients replacement of an extremely valuable hormone that protects against vascular changes, bone degeneration, and overall quality of life should be an easy one. 

Where there is a “window of opportunity” to mitigate risk from age-related metabolic changes which is commonly referred to when prescribing CEE, that does not exist for E2.[7] In fact, in a robust randomized control trial (RCT) that studied over 1,500 women, it was found that the earlier E2 is introduced after menopause and the higher the dose, the more benefit was seen in glucose and lipid parameters, thereby decreasing atherosclerotic risk.[4] 

The plaque buildup that is seen with aging and when supplementing with CEE can lead to an increase in DVTs and CVAs, again not seen with E2.[5,7,8,10,14]

 In addition to inflammation seen in the vessels, breast tissue is also negatively affected by the metabolic changes as women age.[5,12,13] This increased risk of breast cancer was multiplied when they were offered CEE, especially when it was paired with a progestin. It is important to note that breast cancer rates are decreased when women are given E2.[5,12,13]  

Ultimately, the discussion of estrogen vs estradiol should focus on understanding the differences between synthetic estrogen products and bioidentical estradiol. Current evidence supports bioidentical hormone therapy, including estradiol as a beneficial and safe option for menopausal women to preserve their overall health and quality of life.[2,4-14]

Interested in Learning More About Menopause and BHRT?

Understanding the differences between estrogen products is just one component of providing effective, evidence-based menopause care. As research continues to evolve, clinicians need a strong foundation in menopause management and bioidentical hormone replacement therapy (BHRT) to confidently evaluate treatment options and optimize patient outcomes.

If you're interested in deepening your knowledge of menopause, bioidentical hormone therapy, and hormone optimization, consider joining WorldLink Medical's Optimal Medicine Training Series. The series begins with Mastering the Foundations of BHRT, a comprehensive course designed to help providers understand hormones, replacement strategies, and the evidence behind modern hormone therapy.

Learn more and register for Course 1: Mastering the Foundations of BHRT:
https://worldlinkmedical.com/education/conferencecourses/optimal-medicine-training-series/mastering-the-foundations-of-bhrt

This course provides the clinical foundation needed to confidently incorporate hormone optimization into practice and better serve patients navigating menopause and age-related hormone decline.

References

1. U.S. Food & Drug Administration. FDA approves labeling changes to menopausal hormone therapy products. 2026. https://www.fda.gov/news-events/press-announcements/fda-approves-labeling-changes-menopausal-hormone-therapy-products
2. Ruan X, Mueck AO. Primary choice of estrogen and progestogen as components for hrt: a clinical pharmacological view. Climacteric. 2022; 25(5): 443-452. doi:10.1080/13697137.2022.2073811. PMID: 35638518. https://pubmed.ncbi.nlm.nih.gov/35638518/
3. Casper RF. Menopause: clinical features and diagnosis. UpToDate. 2025.https://www.uptodate.com/contents/menopause-clinical-features-and-diagnosis
4. Sriprasert I, Hodis HN, Bernick B, Mirkin S, Mack WJ. Effects of estradiol dose and serum estradiol levels on metabolic measures in early and late postmenopausal women in the replenish trial. J Women’s Health. 2020; 29(8): 1052-1058. doi:10.1089/jwh.2019.8238. PMID: 32644875. https://pubmed.ncbi.nlm.nih.gov/32644875/
5. Graham S, Archer DF, Simon JA, Ohleth KM, Bernick B. Review of menopausal hormone therapy with estradiol and progesterone versus other estrogens and progestins. Gynecol Endocrinol. 2022; 38(11): 891-910. doi:10.1080/09513590.2022.2118254. PMID: 36075250. https://pubmed.ncbi.nlm.nih.gov/36075250/
6. Cintron D, Lahr BD, Bailey KR, et al. Effects of oral versus transdermal menopausal hormone treatments on self-reported sleep domains and their association with vasomotor symptoms in recently menopausal women enrolled in the kronos early estrogen prevent study (keeps). Menopause. 2017; 25(2):145-153. doi: 10.1097/GME.0000000000000971. PMID: 28832429. https://pmc.ncbi.nlm.nih.gov/articles/PMC5771895/
7. Stevenson JC, Baber R, Kagan R, et al. Major adverse cardiovascular events risk in menopausal women treated with oral estradiol/micronized progesterone versus conjugated estrogens/medroxyprogesterone : a claims data analysis in the usa. Climacteric. 2025; 28(6): 682-692. doi: 10.1080/13697137.2025.2509850. PMID: 40773298.  https://pubmed.ncbi.nlm.nih.gov/40773298/
8. Smith NL, Blondon M, Wiggins KL, et al. Lower risk of cardiovascular events in postmenopausal women taking oral estradiol compared with oral conjugated equine estrogens. JAMA Intern Med. 2014;174(1):25-31. doi:10.1001/jamainternmed.2013.11074. PMID: 24081194. https://pubmed.ncbi.nlm.nih.gov/24081194/
9. Chang W, Wang J, Ding D. Menopausal hormone therapy with conjugated equine estrogen is associated with a higher risk of hemorrhagic stroke than therapy with estradiol: a retrospective population-based cohort study. Maturitas. 2022; 165:72-77. doi:10.1016/j.maturitas.2022.07.009. PMID: 35933795. https://pubmed.ncbi.nlm.nih.gov/35933795/
10. Mirkin S, Amadio JM, Bernick BA, Pickar JH, Archer DF. 17β-Estradiol and natural progesterone for menopausal hormone therapy: replenish phase 3 study design of a combination capsule and evidence review. Maturitas. 2015;81(1):28-35. doi:10.1016/j.maturitas.2015.02.266. PMID: 25835751. https://pubmed.ncbi.nlm.nih.gov/25835751/
11. Kantarci K, Lowe VJ, Lesnick TG, et al. Early postmenopausal transdermal 17β-estradiol therapy and amyloid-β deposition. J Alzheimers Dis. 2016;53(2):547-556. doi:10.3233/JAD-160258. PMID: 27163830. https://pubmed.ncbi.nlm.nih.gov/27163830/
12. Lalitkumar PGL, Lundstrom E, Bystrom B, et al. Effects of estradiol/micronized progesterone vs. conjugated equine estrogens/medroxyprogesterone acetate on breast cancer gene expression in healthy postmenopausal women. Int J Mol Sci. 2023;24(4):4123. doi:10.3390/ijms24044123. PMID: 36835533. https://pmc.ncbi.nlm.nih.gov/articles/PMC9959219/
13. Yang Z, Hu Y, Zhang J, Xu L, Zeng R, Kang D. Estradiol therapy and breast cancer risk in perimenopausal and postmenopausal women: a systematic review and meta-analysis. Gynecol Endocrinol. 2017;33(2):87-92. doi:10.1080/09513590.2016.1248932. PMID: 27898258. https://pubmed.ncbi.nlm.nih.gov/27898258/
14. Panay N, Nappi RE, Stute P, et al. Oral estradiol/micronized progesterone may be associated with lower risk of venous thromboembolism compared with conjugated equine estrogens/medroxyprogesterone acetate in real-world practice. Maturitas. 2023;172:23-31. doi:10.1016/j.maturitas.2023.04.004. PMID: 37084589. https://pubmed.ncbi.nlm.nih.gov/37084589/